Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.

Shimoda S, Sakamoto W, Hokamura A, Matsuo Y, Sekigami T, Ichimori S, Iwashita S, Ishii N, Otsu K, Yoshimura R, Nishiyama T, Sakaguchi M, Nishida K, Araki E.

Endocr J. 2019 Aug 29;66(8):745-752. doi: 10.1507/endocrj.EJ19-0179. Epub 2019 Jul 12.

2.

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy.

Langer J, Wolden ML, Shimoda S, Sato M, Araki E.

Diabetes Ther. 2019 Aug;10(4):1347-1356. doi: 10.1007/s13300-019-0635-1. Epub 2019 Jun 5.

3.

Mineralocorticoid Receptor May Regulate Glucose Homeostasis through the Induction of Interleukin-6 and Glucagon-Like peptide-1 in Pancreatic Islets.

Goto R, Kondo T, Ono K, Kitano S, Miyakawa N, Watanabe T, Sakaguchi M, Sato M, Igata M, Kawashima J, Motoshima H, Matsumura T, Shimoda S, Araki E.

J Clin Med. 2019 May 14;8(5). pii: E674. doi: 10.3390/jcm8050674.

4.

Study Design of a Phase II Clinical Trial to Assess the Efficacy and Safety of Eperisone in Japanese Type 2 Diabetes Patients with Risk and Non-risk Alleles of CDKAL1.

Sakakida K, Wei FY, Senokuchi T, Shimoda S, Kakuma T, Araki E, Tomizawa K; Eperisone for Diabetes with Impaired tRNA (EDIT) Study Group.

Acta Med Okayama. 2018 Aug;72(4):423-426. doi: 10.18926/AMO/56182.

5.

Effect of sleep curtailment on dietary behavior and physical activity: A randomized crossover trial.

Tajiri E, Yoshimura E, Hatamoto Y, Tanaka H, Shimoda S.

Physiol Behav. 2018 Feb 1;184:60-67. doi: 10.1016/j.physbeh.2017.11.008. Epub 2017 Nov 9.

PMID:
29129611
6.

Impaired balance is related to the progression of diabetic complications in both young and older adults.

Kukidome D, Nishikawa T, Sato M, Nishi Y, Shimamura R, Kawashima J, Shimoda S, Mizuta H, Araki E.

J Diabetes Complications. 2017 Aug;31(8):1275-1282. doi: 10.1016/j.jdiacomp.2017.05.014. Epub 2017 Jun 4.

PMID:
28610947
7.

Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and obese KK-Ay mice.

Hanatani S, Motoshima H, Takaki Y, Kawasaki S, Igata M, Matsumura T, Kondo T, Senokuchi T, Ishii N, Kawashima J, Kukidome D, Shimoda S, Nishikawa T, Araki E.

J Clin Biochem Nutr. 2016 Nov;59(3):207-214. Epub 2016 Sep 8.

8.

A 1-year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal-bolus insulin therapy (Kumamoto Insulin Degludec Observational study).

Shimoda S, Sato M, Sekigami T, Motoshima H, Yoshimura R, Fukuda K, Matsuo Y, Noda H, Okubo M, Ichimori S, Fujisawa K, Fukunaga M, Araki E; Kumamoto Insulin Degludec Observational (KIDUNA) Study Group.

J Diabetes Investig. 2016 Sep;7(5):703-10. doi: 10.1111/jdi.12496. Epub 2016 Mar 19.

9.

Coexistence of resistance to thyroid hormone and papillary thyroid carcinoma.

Igata M, Tsuruzoe K, Kawashima J, Kukidome D, Kondo T, Motoshima H, Shimoda S, Furukawa N, Nishikawa T, Miyamura N, Araki E.

Endocrinol Diabetes Metab Case Rep. 2016;2016:160003. doi: 10.1530/EDM-16-0003. Epub 2016 Mar 30.

10.

Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.

Shimoda S, Okubo M, Koga K, Sekigami T, Kawashima J, Kukidome D, Igata M, Ishii N, Shimakawa A, Matsumura T, Motoshima H, Furukawa N, Nishida K, Araki E.

Endocr J. 2015;62(2):209-16. doi: 10.1507/endocrj.EJ14-0487. Epub 2014 Nov 11.

11.

Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.

Shimoda S, Iwashita S, Sekigami T, Furukawa N, Matsuo Y, Ichimori S, Goto R, Maeda T, Watanabe E, Kondo T, Matsumura T, Motoshima H, Nishida K, Araki E.

J Diabetes Investig. 2014 May 4;5(3):320-6. doi: 10.1111/jdi.12151. Epub 2013 Oct 22.

12.

Association between circulating leukocyte subtype counts and carotid intima-media thickness in Japanese subjects with type 2 diabetes.

Matsumura T, Taketa K, Motoshima H, Senokuchi T, Ishii N, Kinoshita H, Fukuda K, Yamada S, Kukidome D, Kondo T, Hisada A, Katoh T, Shimoda S, Nishikawa T, Araki E.

Cardiovasc Diabetol. 2013 Dec 27;12:177. doi: 10.1186/1475-2840-12-177.

13.

Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.

Shimoda S, Iwashita S, Ichimori S, Matsuo Y, Goto R, Maeda T, Matsuo T, Sekigami T, Kawashima J, Kondo T, Matsumura T, Motoshima H, Furukawa N, Nishida K, Araki E.

Endocr J. 2013;60(10):1207-14. Epub 2013 Aug 3.

14.

Regulation of TNFα converting enzyme activity in visceral adipose tissue of obese mice.

Kawasaki S, Motoshima H, Hanatani S, Takaki Y, Igata M, Tsutsumi A, Matsumura T, Kondo T, Senokuchi T, Ishii N, Kinoshita H, Fukuda K, Kawashima J, Shimoda S, Nishikawa T, Araki E.

Biochem Biophys Res Commun. 2013 Jan 25;430(4):1189-94. doi: 10.1016/j.bbrc.2012.12.086. Epub 2012 Dec 27.

PMID:
23274494
15.

Effects of olmesartan, an angiotensin II receptor blocker, on peripheral insulin sensitivity in Japanese subjects with type 2 diabetes and hypertension.

Shimoda S, Goto R, Furukawa N, Tsuruzoe K, Kawashima J, Iwashita S, Maeda T, Ichimori S, Ichinose K, Nishida K, Araki E.

Intern Med. 2012;51(16):2091-6. Epub 2012 Aug 15.

16.

Anti-atherosclerotic potential of dihydropyridine calcium channel blockers.

Ishii N, Matsumura T, Shimoda S, Araki E.

J Atheroscler Thromb. 2012;19(8):693-704. Epub 2012 May 17. Review.

17.

The impact of Ca²⁺/calmodulin-dependent protein kinase II on insulin gene expression in MIN6 cells.

Suefuji M, Furukawa N, Matsumoto K, Oiso H, Shimoda S, Yoshinaga T, Matsuyama R, Miyagawa K, Kondo T, Kawashima J, Tsuruzoe K, Araki E.

Biochem Biophys Res Commun. 2012 May 18;421(4):801-7. doi: 10.1016/j.bbrc.2012.04.091. Epub 2012 Apr 25.

PMID:
22554507
18.

Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes.

Ichimori S, Shimoda S, Goto R, Matsuo Y, Maeda T, Furukawa N, Kawashima J, Kodama S, Sekigami T, Isami S, Nishida K, Araki E.

J Diabetes Investig. 2012 Mar 28;3(2):179-84. doi: 10.1111/j.2040-1124.2011.00147.x.

19.

Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.

Matsumura T, Taketa K, Shimoda S, Araki E.

J Diabetes Investig. 2012 Feb 20;3(1):11-23. doi: 10.1111/j.2040-1124.2011.00182.x. Review.

20.

A case of cortisol producing adrenal adenoma associated with a latent aldosteronoma: usefulness of the ACTH loading test for the detection of covert aldosteronism in overt Cushing syndrome.

Kukidome D, Miyamura N, Sakakida K, Shimoda S, Shigematu Y, Nishi K, Yamashita Y, Eto M, Sasano H, Araki E.

Intern Med. 2012;51(4):395-400. Epub 2012 Feb 15.

Supplemental Content

Loading ...
Support Center